PO.TB04.04 · 肿瘤生物学

IFNalpha通过诱导蛋白质翻译使中性粒细胞极化为粒细胞型MDSC

IFNalpha polarizes granulocytic MDSCs from neutrophils by inducing protein translation

编号 6082 展板 28 时间 4/21 02:00–05:00 区域 Section 26 主讲 Juanita Merchant, MD;PhD
分会场 In Vivo Models 2: Genetically Engineered Mouse Models, PDXs, Syngeneic Models
该海报暂无可下载的资料 AACR 官方页面

作者与单位 Authors & Affiliations

Juanita L. Merchant, Lin Ding

Medicine, Univ. of Arizona Health Sciences Ctr., Tucson, AZ

摘要 Abstract

中文摘要
肿瘤免疫微环境中广泛存在的异质性是困扰实体瘤免疫治疗失败的一个难题,因为它阻碍了明确各类细胞特定弱点、从而更精准地开发治疗手段。髓源性抑制细胞(MDSC)是一群异质性的免疫抑制性单核细胞与粒细胞(中性粒细胞),其与癌症生存不良之间的关联尚未被充分了解。大多数MDSC表现出未成熟粒细胞的特征(Gr-MDSC),并通过分泌活性氧和活性氮(RONS)发挥T细胞抑制作用。尽管产生RONS,Gr-MDSC仍能通过动员保护蛋白质翻译的机制而存活数天。一种令人关注的MDSC亚型是由其对1型干扰素(IFNalpha)的极化反应所定义的,我们此前在慢性感染幽门螺杆菌并伴胃化生的小鼠中曾鉴定出该亚型,提示感染幽门螺杆菌的胃可使中性粒细胞极化并获得免疫抑制表型。我们假设,IFNalpha通过增加中性粒细胞在获得Gr-MDSC表型过程中改变其代谢活动所需的蛋白质合成,从而启动中性粒细胞的重编程。我们对来自5组因内镜检查而就诊患者的活检组织进行了scRNA-Seq分析,这些患者分别为:无胃部异常、H. pylori阳性(Hp)、伴肠化生(IM)或胃腺癌(GAC),结果发现最初存在于IM中的IFN极化MDSC群体在GAC中显著增多,但在正常及Hp感染患者中未检测到,证实IM一旦出现即发生IFN极化Gr-MDSC的极化。我们证明IFN极化Gr-MDSC在体外由中性粒细胞重编程而来,且需要蛋白质翻译的诱导。为分析翻译,我们用IFNalpha处理来自小鼠骨髓或人PBMC的原代粒细胞培养物,在培养物中加入20μM的O-炔丙基嘌呤霉素(OPP)孵育后通过流式细胞术定量蛋白质翻译,并用EdU定量增殖。体内分析则通过在小鼠安乐死前给予OPP进行。在体外中性粒细胞培养中,约28%的极化中性粒细胞为CD11b+Gr-1+ MDSC,其中85%的这些Gr-MDSC在增殖增加的同时诱导了其蛋白质合成。对小鼠和人胃组织的scRNA-Seq分析均显示未折叠蛋白反应(UPR)介质(如CHOP)的诱导。总之,1型IFN使中性粒细胞极化为Gr-MDSC需要蛋白质翻译的诱导,揭示了可能被靶向以重编程免疫抑制性肿瘤微环境的潜在代谢通路。
查看英文原文 English abstract
The extensive heterogeneity in the tumor immune microenvironment is a problem plaguing immune-based treatment failures for solid tumors because it prevents defining the specific vulnerabilities of the various cells to develop treatments with greater precision. Myeloid-derived suppressor cells (MDSCs) are a heterogenous collection of immunosuppressive monocytes and granulocytes (neutrophils) whose link to poor cancer survival is not well understood. Most MDSCs exhibit features of immature granulocytes (Gr-MDSCs) and exert their T cell suppression by secreting reactive oxygen and nitrogen species (RONS). Gr-MDSCs can survive for days by recruiting mechanisms to protect protein translation despite generation of RONS. One MDSC subtype of interest is defined by their polarization in response to type 1 interferon (IFNalpha) that we previously identified in chronic Helicobacter -infected mice with gastric metaplasia, suggesting that a Helicobacter -infected stomach polarizes neutrophils to acquire an immunosuppressive phenotype. We hypothesize that IFNalpha initiates neutrophil reprogramming by increasing protein synthesis required to alter their metabolic activities as they acquire the Gr-MDSC phenotype. We performed scRNA-Seq on biopsies from 5 groups of patients referred for endoscopy and showed no gastric abnormalities, were H. pylori + (Hp), had intestinal metaplasia (IM) or gastric adenocarcinoma (GAC) and identified that the IFN-polarized MDSC population initially present in IM increased substantially in GACs but was not detected in normal and Hp -infected patients, confirming the polarization of IFN-polarized Gr-MDSCs once IM appears. We showed that the IFN-polarized Gr-MDSCs re-programmed from neutrophils in vitro and required induction of protein translation. To analyze translation, we treated primary cultures of granulocytes from mouse bone marrow or human PBMCs with IFNalpha and quantified protein translation by flow cytometry after incubating the cultures with 20µM O-propargyl-puromycin (OPP) and proliferation with EdU. In vivo analysis was performed by administering OPP to mice before euthanization. In the in vitro neutrophil cultures, about 28% of the polarized neutrophils were CD11b + Gr-1 + MDSCs, and 85% of these Gr-MDSCs induced their protein synthesis coincident with increased proliferation. scRNA-Seq analysis of both mouse and human gastric tissues demonstrated induction of mediators of the unfolded protein response (UPR), e.g., CHOP. In summary, polarization of Gr-MDSCs by type 1 IFNs from neutrophils requires induction of protein translation, revealing possible metabolic pathways that may be targeted to reprogram the immunosuppressive tumor microenvironment.
利益披露 Disclosure
J. L. Merchant, None.. L. Ding, None.

← 返回 AACR 2026 检索